

KILITCH DRUGS (INDIA) LIMITED

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2016

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN. L24239MH1992PLC066718

Rs. In Lacs

Sr. No.	Particulars	STANDALONE			
		Three Months Ended		Year Ended	
		30/06/16	31/03/16	30/06/15	31/03/16
		Unaudited	Audited	Unaudited	Audited
1	Income from operations				
	(a) Net Sales/income from operations(net of Excise)	662.60	667.53	395.74	2082.46
	(b) Other operating income	2.06	10.31	3.67	19.70
	Total income from Operations (Net)	664.66	677.84	399.41	2102.16
2	Expenses				
	(a) Cost of materials consumed	314.60	197.19	298.35	891.84
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(9.59)	29.53	(13.24)	(18.61)
	(c) Employee Benefit Expenses	72.59	90.10	85.26	342.20
	(d) Depreciation and Amortisation Expenses	41.19	41.28	39.14	161.25
	(e) Export Product Registration Charges	36.84	46.58	14.65	149.28
	(f) Other Expenses	306.92	375.15	285.44	1098.66
	Total Expenses	762.55	779.82	709.60	2624.62
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(97.89)	(101.96)	(310.19)	(522.46)
4	Other Income	23.43	154.91	57.62	273.51
5	Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)	(74.46)	52.95	(252.57)	(248.96)
6	Finance Costs	0.00	0.00	0.00	0.00
7	Profit / (Loss) from ordinary activities before exceptional items (5-6)	(74.46)	52.95	(252.57)	(248.96)
8	Exceptional Items	0.00	0.00	0.00	0.00
9	Profit / (Loss) from ordinary activities before tax (7+8)	(74.46)	52.95	(252.57)	(248.96)
10	Tax Expenses				
	Current Tax	0.00	0.00	0.00	0.00
	Deferred Tax	(3.26)	(5.43)	(3.52)	(43.61)
	Tax Adjustments of Earlier years	0.00	0.00	0.00	0.00
11	Net Profit / (Loss) from ordinary activities after tax (9-10)	(71.20)	58.38	(249.05)	(205.35)
12	Extra Ordinary Items (net of tax expenses)	0.00	0.00	0.00	0.00
13	Net Profit / (Loss) for the period (11+12)	(71.20)	58.38	(249.05)	(205.35)
14	Paid-Up equity share capital (Face Value Rs 10 per share)	1323.18	1323.18	1323.18	1323.18
15	Reserves excluding Revaluation Reserve [As per the latest Audited Balance Sheet]				10469.01
16.i	Earnings per share (before extra ordinary items) (F.V. of Rs.10/-each) (not annualised):				
	(a) Basic	(0.54)	0.44	(1.88)	(1.55)
	(b) Diluted	(0.54)	0.44	(1.88)	(1.55)
16.ii	Earnings per share (after extra ordinary items) (F.V. of Rs.10/-each) (not annualised):				
	(a) Basic	(0.54)	0.44	(1.88)	(1.55)
	(b) Diluted	(0.54)	0.44	(1.88)	(1.55)

Notes:

- 1 The above results as reviewed by the audit committee have been taken on record by the Board of Directors at their meeting held on 12th August, 2016.
- 2 The Company has operated only in one reportable segment i.e. Pharmaceuticals.
- 3 The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods. Figures of the quarter ended 31-03-2016 are the balancing figures between the audited figures in respect of the full financial year F.Y. 2015-16 and the published year to date figures upto the third quarter of the said financial year.



For and on behalf of Board

 Mukund P. Mehta
 Managing Director



Place :
Date: Mumbai
12th August, 2016

**A. M. GHELANI & COMPANY
CHARTERED ACCOUNTANTS**

224, Champaklal Industrial Estate,
Sion-Kaliwada Road, Sion (East),
Mumbai - 400 022.
Tel : 2402 4909 / 8739
Fax : 2407 1138
E-mail : amghelaniandco@gmail.com

AJIT M. GHELANI
B.Com (Hons), F.C.A., GRAD. C.W.A.

CHINTAN A. GHELANI
B.Com (Hons), F.C.A., C.S

INDEPENDENT AUDITORS' REVIEW REPORT

To,
The Board of Directors
Kilitch Drugs (India) Limited

LIMITED REVIEW REPORT OF THE UNAUDITED STANDALONE RESULTS OF KILITCH DRUGS (INDIA) LIMITED FOR THE QUARTER ENDED 30th JUNE, 2016

1. We have reviewed the accompanying statement of unaudited standalone financial results of Kilitch Drugs (India) Limited for the quarter ended 30th June, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the Accounting Standards issued under the Companies (Accounting Standards) Rules, 2006 which continue to apply as per Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rule, 2014 and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/15/2015 dated 30th November, 2015 and SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A. M. Ghelani & Company
Chartered Accountants
FRN: 103173W


Chintan Ghelani
Partner

Membership No.: 104391



Place : Mumbai
Dated : 12th August, 2016

Enclosed: Unaudited financial results for the quarter ended 30th June, 2016 of Kilitch Drugs (India) Limited.